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Abstract 
Background: Malaria remains a global health issue with the burden unevenly distributed to the disadvantage of the 
developing countries of the world. Poverty contributes to the malaria burden as it has the ability to affect integral 
aspects of malaria control. There have been renewed efforts in the global malaria control, resulting in reductions in 
the global malaria burden over the last decade. However, the development of resistance to artemisinin-based combi-
nation therapy threatens the sustainability of the present success in malaria control. Anti-malarial drug use practices/
behaviours remain very important drivers of drug resistance. This study adopted a social epidemiological stance in 
exploring the underlying socioeconomic factors that determine drug use behaviours promoting anti-malarial drug 
resistance.
Methods: A qualitative approach, involving the use of interviews, was used in this inquiry to explore the existing 
anti-malarial drug use practices in the Nigerian population; and the different socioeconomic factors influencing the 
behaviours.
Results: The significant malaria treatment behaviours influenced by socioeconomic factors in this study were the 
practice of ‘mixing’ drugs for malaria treatment, presumptive treatment, sharing of malaria treatment course, and the 
use of anti-malaria monotherapies. All the rural dwellers in this study reported they have mixed drugs for malaria 
treatment. When symptoms were experienced, socio-economic factors, like type of settlement, income level and 
occupation, tended to determine the treatment behaviour and, therefore, informed and determined the experience 
of the illness.
Discussion: Social and economic contexts can influence behaviours as they contribute in shaping norms and in 
creating opportunities that promote certain behaviours. As shown in this study, income level and type of settlement, 
as structural factors, affect the decision on where to seek malaria treatment and whether or not a malaria diagnostic 
test will be used prior to treatment. One of the dangers of using the mixed anti-malarial drugs is that it offers a safe 
route for the sale of expired and fake anti-malarial drugs as the mixed drugs are not sold or dispensed in their original 
packets.
Conclusions and recommendations: Population-wide improvements in income, education, environmental and 
structural conditions of rural dwellers in malaria-endemic settings will encourage behavioural change on how anti-
malarial drugs are used.
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Background
Malaria is a parasitic infection caused by species of Plas-
modium parasites [1]. Although a global health issue, its 
burden is unevenly distributed to the disadvantage of the 
developing countries of the world [2, 3]. Africa is still the 
leading region in terms of malaria burden. This region 
accounts for majority (80%) of the malaria cases as well 
as malaria-associated deaths (90%) globally [1]; with chil-
dren under 5 years of age at most risk of malaria infec-
tion. Nigeria, a middle-income country in sub-Saharan 
Africa, is among the countries with the highest malaria 
burden in the world, with 32% of global malaria mortal-
ity occurring in this country and 97% of the population at 
risk of malaria infection [4]. Some factors that drive the 
persistence of malaria in the Nigerian population are: the 
availability of conducive environment for vector breeding 
[5]; the Nigerian healthcare system; and the high level of 
poverty in Nigeria [6], where about 46% of the population 
live below the World Bank poverty line of $1.25 per day 
[7].
Some features of the Nigerian healthcare system that 
contribute to the persistence of the disease burden in 
this population (by constituting a major barrier to early 
and effective treatment) include the lack of universal and 
equitable access to primary healthcare as this is the level 
where conditions like malaria infection are managed 
[8]; and the current government policy of payment for 
healthcare in all public health facilities at the point of use 
[8, 9]. It is established that socioeconomic factors are key 
drivers of health disparities between and within coun-
tries. As a socioeconomic issue, the high level of poverty 
in Nigeria, as with most malaria endemic countries, is an 
important factor that reinforces the persistent malaria 
burden in Nigeria.
Indeed, a strong relationship exists between poverty 
and malaria [10]. This relationship is evident in the fact 
that most malaria endemic countries are also among the 
poorest countries of the world. Poverty contributes to 
the malaria burden as it has the ability to affect integral 
aspects of malaria treatment-seeking behaviours [10], 
including access to preventive measures and treatment—
in relation to affordability, acceptability and availability—
[11], and adherence to treatment.
Presently, there have been renewed efforts in the 
global malaria control with several organizations and 
non-endemic countries increasingly getting involved 
in the fight against malaria [12, 13]. These efforts have 
resulted in reduction in the global malaria burden over 
the last decade [14]. The current achievement is mostly 
attributed to the increase in malaria research funding, 
and scale-up of interventions against malaria, including 
insecticides-treated nets (ITNs), indoor residual spraying 
(IRS), rapid diagnostic testing (RDT), and importantly, 
the use of artemisinin-based combination therapy (ACT) 
[15]. There has been significant improvement in access, 
availability and affordability of ACT in malaria endemic 
regions [14].
ACT is presently the World Health Organization 
(WHO) recommended first-line treatment for uncom-
plicated malaria [1]. This recommendation has been 
adopted by most malaria-endemic countries, like Nige-
ria, where artemether-lumefantrine is the first-line treat-
ment for uncomplicated malaria cases [4, 16]. In relation 
to previously used anti-malarial drugs, artemisinin drugs 
are very effective in parasite clearance and can relief the 
malaria symptoms faster [17, 18]. However, the develop-
ment of resistance to ACT (which has been confirmed in 
five countries of Southeast Asia (SEA): Cambodia, Lao 
PDR, Myanmar, Thailand and Viet Nam [1, 19, 20] poses 
a major threat to its efficacy and use as first-line treat-
ment. This also threatens the sustainability of the present 
success in malaria control [21].
Similar to the artemisinin class drugs, the development 
of resistance to most of the previously used anti-malarial 
drugs (such as chloroquine, sulfadoxine-pyrimethamine, 
mefloquine) originated from South East Asia (SEA). Nev-
ertheless, the burden and effects of resistance are usually 
borne more by the African region that accounts for most 
of the global malaria cases [1]. Considering the quick 
and widespread of previous cases of resistance to anti-
malarial drugs from the SEA to Africa, the African region 
stands at risk of spread of artemisinin resistance [22, 23].
Importantly, the mechanism behind the development 
and spread of anti-malarial drug resistance is a com-
plex one with multiple factors in play—such as drug use 
practices/behaviours, drug half-life, transmission inten-
sity, clone multiplicity, parasite density, host immunity, 
within-host dynamics and the genetic basis of drug resist-
ance [24]. Nevertheless, anti-malarial drug use practices/
behaviours of presumptive treatment, drug overuse, use 
of sub-therapeutic doses, non-adherence to the treat-
ment regime, among others, remain very important driv-
ers of drug resistance as they can affect some of the other 
factors [24]. In addition, unlike most of the other causal 
factors to anti-malarial drug resistance, drug use prac-
tices can be controlled through changes in human behav-
iours and activities [25]. In order to encourage changes in 
human behaviours around the use of anti-malarial drugs, 
there is need for a good understanding of the factors that 
play important roles in determining these behaviours, 
and how they interact with one another in influencing 
these behaviours.
Evidently, most of the studies on anti-malarial drug 
resistance have been conducted from parasitologi-
cal [26–29] and pharmacological [21, 24] perspectives. 
These studies, while adopting a biomedical approach, 
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have mostly looked at the molecular, biological and/or 
pharmacokinetic aspects of anti-malarial drug resist-
ance. Although they have contributed to the fight against 
resistance to anti-malarial drugs by providing evidence 
on the mechanisms involved, the persistent develop-
ment and spread of resistance to anti-malarial drugs by 
the Plasmodium parasites despite these efforts calls for 
additional approaches in studying this important pub-
lic health issue. In order to have a wider picture of the 
issue of anti-malarial drug resistance, there is need for a 
psychosocial perspective that will explore the underlying 
causes of human behaviours that promote the develop-
ment and spread of resistance. This will help to protect 
the efficacy of malaria treatments by informing effec-
tive behavioural change campaigns. Currently, there is 
no existing qualitative enquiry that focused specifically 
on exploring the interactions between socioeconomic 
factors, anti-malarial drug use behaviours and drug 
resistance.
Consequently, a social epidemiological stance was 
adopted in this study. As a sub-discipline of epidemiol-
ogy, social epidemiology is a perspective on health that 
is concerned with the connection between social sys-
tems and population health [30]. It deals with the social 
distribution and determinants of states of health [31]. 
By adopting a psychosocial approach to health, social 
epidemiologists see health outcomes as not necessarily 
products of biological factors alone, but also of socio-
structural forces acting around individuals [32]. In addi-
tion, evidences from existing studies have shown that 
health-related behaviours are not randomly distributed 
in nature but are socially and economically patterned 
[31]. In malaria treatment-seeking, socioeconomic struc-
tures can constrain choices of where to seek treatment, 
affect knowledge level and perception about malaria, 
and encourage behaviours that might be formed as cop-
ing strategies to cushion the effects of these forces. This 
study explored the underlying socioeconomic factors that 
determine drug use behaviours promoting anti-malarial 
drug resistance.
Research aim
The aim of this study is to explore the anti-malarial drug 




This study was conducted in two areas, Imo state and 
Abuja in the southern and northern parts of Nigeria, 
respectively (see Fig.  1 showing a map of Nigeria with 
the study areas highlighted in green). The interviewees 
were selected from a rural and an urban area from each 
of the states, making a total of four (4) study sites—Abuja 
municipal (Urban); Zuba (rural); Owerri municipal 
(urban) and Ihitte-uboma (Rural).
Nigeria is a sub-Saharan African country with a popu-
lation of about 177 million people [33], and about 53% of 
the population living in the rural areas [34]. The coun-
try has a land mass of 923,768 square kilometres and a 
tropical climate with two seasons: the wet and the dry 
seasons. The annual rainfall ranges between 550  mm in 
some part of the north (mainly in the fringes of Sahara 
desert) to 4000 mm (in the coastal region around Niger 
delta area in the south). The temperature in Nigeria oscil-
lates between 25 and 40 °C.
The climatic and geographic features of Nigeria make 
it a conducive site for high malaria transmission. All the 
states in Nigeria are holoendemic for malaria, and trans-
mission is usually year round. However, the wet or rainy 
season is the peak malaria transmission season in Nige-
ria. In addition, the duration of the peak transmission 
season differs in different locations with the areas in the 
north having shorter duration of transmission (approxi-
mately 3 months) than the south (almost year round) 
[5]. Plasmodium falciparum is the most prevalent (97%) 
malaria parasite specie in Nigeria [5].
Apart from the geographical and climate change dif-
ferences between the northern and southern Nigeria; 
as with most countries in the world, like England, the 
north–south divide exists in Nigeria with regards to 
predominant cultures, religion, educational level, type 
of occupation and level of urbanization. As such, to get 
a northern and southern perspective of the issue under 
study, Imo state in the south and Abuja in the north were 
selected for this study. Other factors, like participants 
and researchers’ health and safety, were considered in 
choosing these sites.
Study design
A qualitative approach, involving the use of interviews, 
was used in this inquiry to explore the existing anti-
malarial drug use practices in the Nigerian population; 
and the different socioeconomic factors influencing the 
behaviours. This study is part of a larger study on anti-
malarial drug resistance in Nigeria. Fifteen in-depth, 
face-to-face interviews were conducted with household 
heads (thirteen), a drug vendor and a pharmacy assistant 
from the four locations this study covered.
Sampling and recruitment
The inclusion criteria for participants in this study were:
  • Participants must be at least 18 years of age.
  • Participants must be resident in Nigeria.
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  • Participants must be household heads who bear the 
financial cost of malaria treatment for themselves 
and members of their household. The reason for 
this is to ensure that those who can provide accurate 
information on the financial cost of malaria treat-
ment to their household are recruited.
  • In addition to the above, a drug vendor and a phar-
macy assistant from the study sites were interviewed 
to help interpret the findings from the participants.
To ensure that participants who can recall and pro-
vide relevant information to answer the research ques-
tion were selected, a systematic theoretical sampling 
technique [35] was used in selecting participants for this 
study. This technique involved continuous sampling and 
data collection until saturation was achieved; that is, the 
point when no new information or category, in relation 
to the issue under study, was emerging from subsequent 
interviews [36]. Consequently, the data collection and 
analysis were simultaneously conducted with each inter-
view transcribed and analysed prior to the conduct of the 
next interview. With this strategy, emerging codes were 
considered and incorporated into subsequent interviews. 
This enabled the researcher to probe or elicit further 
explanations on some behaviours or experiences identi-
fied in previous interviews. This strategy was also impor-
tant in determining when saturation was achieved in this 
study. In all, fifteen (15) individual in-depth interviews 
were conducted with fifteen participants.
Prior to the conduct of each interview, the interviewer 
made a brief first contact with each participant as an ice-
breaker strategy to improve acceptance, trust and com-
munication. It was during these first meetings that the 
participant information sheet was given to the partici-
pants and verbally explained. Also, during this contact, 
the researcher made some observations like the willing-
ness or reluctance of the individuals to participate in the 
study with the aim of excluding those who show reluc-
tance and are uncomfortable all through the meeting. All 
individuals approached agreed to this first meeting and 
were included in this study afterwards as they all met 
these criteria. Subsequently, the interviewer and the par-
ticipants agreed on a convenient day, time and venue for 
the interview.
A written informed consent was obtained from par-
ticipants prior to the interview. In addition to this, a 
confirmatory verbal informed consent was obtained 
Fig. 1 Map of Nigeria with study areas highlighted in green
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and audio recorded at the beginning of each interview. 
All participants consented to the interview being audio 
recorded.
Confidentiality and anonymity were assured to all par-
ticipants. These were maintained all through the study 
by assigning identification codes to each participant and 
by storing the interview data securely in a password pro-
tected storage device. Prior to the commencement of 
each interview, participants were informed of their right 
to partake or not, and to withdraw or ask the interviewer 
to stop the interview at any point. Participants were also 
given the contact detail of the researchers and the Uni-
versity of Sunderland Research Ethics Committee for any 
subsequent concerns. A 1-week period from the day of 
the interview was given for the participants to contact 
the researchers if they decide to withdraw their interview 
account from the study.
The interviews were conducted by the first author 
whose familiarity of the study population and previous 
research experiences in Nigeria were very important in 
the recruitment and conduct of the interviews. The first 
author, having lived in Nigeria for more than 20 years, 
had a grounded knowledge and understanding of the 
local languages and culture of the study population.
Furthermore, the interview questions were centred on 
participants’ experiences and behaviours in using anti-
malarial drugs. Prior to the main interview, the interview 
schedule was piloted with two participants of similar 
characteristics with the main participants. The inter-
views were held at community venues, which partici-
pants selected and were already familiar with. In all, the 
interview time was between 30–35 min. Interviews were 
conducted in English and two Nigerian languages (Hausa 
and Igbo languages). Socio-demographic data were col-
lected using a brief questionnaire administered to each 
participant at the end of the interview.
Data processing and analysis
All the interview records were transcribed verbatim from 
audio to a written form by the interviewer on the same 
day they were conducted. This helped to ensure that the 
memory and observations during the interviews were 
retained. Where necessary, the interview transcripts were 
translated from local language to English.
The thematic analysis method, as outlined by Braun 
and Clarke [37] was used in analysing the interview data. 
This involved firstly, a comprehensive reading and re-
reading of all the data set (transcript). In the second step, 
relevant pieces and expressions from the transcript were 
labelled or coded. Coding, in this study, was conducted at 
a descriptive level with the aim of summarizing the main 
concept of each statement from the interview thereby 
retaining the information from the statement. The third 
step involved further review of the codes for patterns and 
linking related codes together to form categories. The 
grouping into categories was based on not just exact or 
close similarities; but codes that had something in com-
mon or are linked in some ways, that might not seem so 
at the face value, were also grouped together as a cate-
gory [38]. The final step was about developing key themes 
from the categories. The themes were developed around 
reported practices and behaviours in seeking malaria 
treatment that were connected. To achieve this, the cat-
egories were considered for relevance and how they con-
nect and interact with one another. Categories that were 
similar or informed others were combined to build up a 
key theme. For the meaning of some key terms used in 
this study, see Table 1.
Socio‑demographic description of participants
The socio-demographic characteristics of the partici-
pants are shown in Table  2. Overall, 53.3% of the par-
ticipants were females. The mean age of the participants 
was 40 years. The most common occupation of the par-
ticipants was farming. Almost half (46.7%) of the par-
ticipants reported they earn below the current Nigerian 
minimum wage of eighteen thousand Naira (₦18,000) 
(about £64) per month. Seventy three percent (73%) of 
the participants had at least some secondary education. 
Urban dwellers constituted 53.3% of the participants, see 
Table 2.
Issues of validity and reliability
Lincoln and Guba [39] argued that approaches to the 
validity and reliability of quantitative research were not 
appropriate for qualitative studies and they suggested 
credibility, transferability, dependability, and confirmabil-
ity as more appropriate criteria. Credibly is ensuring that 
Table 1 Key terms used and their meaning in the context of this study
Terms Meanings
Pharmacy Used to refer to the registered pharmacy shops that are usually found in the cities. These shops are usually owned or run by a 
trained pharmacist. Some pharmacies in Nigeria are however run by pharmacy attendants or nurses
Chemist/drug vendors Used to refer to drug vendors or patent medicine vendors in the study setting. These are usually traders with little or no 
pharmaceutical trainings who either hawk or sell drugs in a small shop. They are mostly common in the rural and suburban 
areas in Nigeria. The term chemist and drug vendors were used interchangeably in this study
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the findings of a qualitative study are credible and actu-
ally reflect the situation under investigation. Merriam 
and Tisdell [40] posed the question “How congruent are 
the findings with reality?”. This was addressed through the 
use of the respondent’s own words to back up claims and 
by ensuring the outline of the categories was reflective of 
the interview transcripts. Shenton [41] also suggests that 
a wider range of respondents can add to the credibility 
of the study. Respondents were chosen from a range of 
socio-economic groups and from rural and urban set-
tings. A range of views was, therefore, represented and 
differences and similarities among the respondents were 
highlighted in the report. Another approach was vali-
dation of the data from the participants themselves (by 
summarizing their accounts during the interview and 
asking them for a validation of this) and from other par-
ticipants (through constant comparative method to vali-
date the experiences of other participants). Furthermore, 
the interviewing researcher’s familiarity with the study 
setting was very important in establishing a good com-
munication with the participants, and understanding the 
social context of the study population—language, culture, 
social structure, and healthcare system.
Dependability refers to the internal consistency. It is 
recognized that in qualitative research, the theoreti-
cal position of the researcher can affect the direction of 
the analysis. This factor is recognized, but this study was 
an exploration of relatively concrete behaviour and the 
dependability largely was achieved through the quality 
of the data analysis. Thematic analysis [37] was used as 
the method of analysis and a clear process was followed, 
open to scrutiny. The process of analysis was carried out 
by one of the researchers and then reviewed by the other 
researchers. All researchers were involved in the discus-
sions and decisions in the analysis of the data—for exam-
ple, in deciding which categories constitute a key theme 
from the analysis.
Indeed, confirmability, which refers to the objectivity 
of the study, can be complex in qualitative research as 
the researcher will bring his or her particular theoretical 
position. The key issue here is whether the data analysis 
was logical and consistent, and if the researchers were 
transparent in all processes; this was a guiding principle 
in the study design. Transferability equates to external 
validity, and again in qualitative research this can be dif-
ficult as samples are small and often not representative. 
Generalization is about: can the findings be transferred 
to another setting or is the presentation of the data clear 
enough to allow the reader to do this? The sample was 
small and examined inhabitants of only two Nigerian 
areas, however it did identify strategies and behaviours 
which allow comparison and in this sense transferability 
was achieved.
Results
The social structures existing within societies and their 
socioeconomic indicators are usually based on charac-
teristics that are valued in the society—educational level, 
income level, type of settlement, occupation, employ-
ment status, among others. As indicators of socio-struc-
tural position within the society, an individual’s level of 
socioeconomic measures can determine the likelihood 
of healthy or unhealthy exposures, behaviours and out-
comes [42].
Several key themes emerged from the analysis of the 
interview data. The themes were developed around the 
anti-malarial drug use behaviours reported, and their 
Table 2 Socio-demographic description of participants
Characteristics Number (%)
Total no. of participants 15 (100)
 Household heads [13]
 Drug vendor [1]
 Pharmacy attendant [1]
Sex
 Males 7 (46.7)
 Females 8 (53.3)
Age
 Mean age 40
 Mode age 31
Relationship status
 Single 3 (20)
 Married 6 (40)
 Widowed 6 (40)
Educational level
 No formal education 1 (6.7)
 Some primary school education 3 (20)
 Some secondary school education 2 (13.3)
 O’level/SSCE holder 2 (13.3)
 Tertiary education/degree 4 (26.7)
 Post graduate degree 3 (20)
Income level
 Below ₦18,000 (£63) 7 (46.7)
 ₦18,000 to ₦50,000 (£64 to £177) 1 (6.7)
 ₦50,001 to ₦100,000 (£178 to £355) 2 (13.3)
 ₦100,001 to ₦300,000 (£356 to £1065) 3 (20)
 Above ₦300,000 (£1065) 2 (13.3)
Type of settlement
 Urban 7 (46.7)
  Owerri in Imo state [2]
  Abuja Municipal city [5]
 Rural 8 (53.3)
  Nkwumeato community in Imo state [4]
  Zuba community in Abuja [4]
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associated socioeconomic factors. The socioeconomic 
factors identified in this study—income level, type of 
settlement, educational level and occupational/job type- 
are all related to one another with some (for example, 
educational and income levels) acting as determinants 
to the others. The significant malaria treatment behav-
iours influenced by socioeconomic factors in this study 
were ‘mixing’, presumptive treatment of malaria, the use 
of drug vendors, sharing of drugs, and the use of anti-
malarial monotherapies.
The Donabedian model, which was initially developed 
to serve as an evaluative framework for quality of health-
care [43], has been widely used in studying other aspects 
of healthcare [44]. It assumes three main components 
in studying health outcomes: Structure, Process and 
Outcomes [45–47]. These three domains work in uni-
directional way with each domain influencing the next. 
This was an appropriate way of organising the categories 
established through the analysis of the interviews.
In applying the Donabedian model to this study 
(see Fig.  2 of an adapted Donabedian model showing 
study findings), the ‘structure’ represents all the fac-
tors that affect the context in which malarial treatment 
is sought. These factors control how patients and pro-
viders act in seeking and providing malaria treatment 
respectively. This includes background characteristics 
of the patient like socioeconomic factors (measures of 
educational level, level of income and wealth, type of 
settlement and occupational type) as well as socio-cul-
tural factors (like beliefs, norms, and constructions). 
The structures in this study were identified from the 
participants’ interview accounts as well as the socio-
demographic questionnaires completed by all the 
participants. These structural factors influence the 
‘process’.
The ‘process’ represents practices and behaviours of 
the participants in treating malaria, which are prod-
ucts of the interaction with the structures. This includes 
reported behaviours like drug ‘mixing’ for malaria treat-
ment, presumptive treatment, non-adherence to treat-
ment guideline, use of monotherapies, among others. 
These behaviours were influenced by the structural fac-
tors, which have the ability to limit people’s choices, 
how they seek malaria treatment and how they use anti-
malarial drugs.
Importantly, the process subsequently determines the 
‘outcome’ which can be in the form of treatment fail-
ure, drug resistance, effective treatment or death. Most 
of the behaviours identified through the interviews that 
constitute the ‘process’ have the tendency to encourage 
the development and/or spread of anti-malarial drug 
resistance.
Death
Fig. 2 Adapted Donabedian model showing study findings
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Structure
Socioeconomic factors
As earlier stated, socioeconomic factors like income 
level, type of settlement and educational levels constitute 
structures that can enhance or endanger a population’s 
health. These factors were reported to affect the way 
malaria treatment is sought and how anti-malarial drugs 
are used. For instance, educational level affects one’s abil-
ity to read and understand written instructions on how to 
administer anti-malarial drugs.
‘Yes. But even if they write it, did I go to school? 
What I know is that way they have shown me to take 
it, that’s the way I follow’ (Female, rural area).
‘Let me say the poor condition that some of us we are 
living in because we don’t have access to eh this eh 
hospitals –the so called hospitals they are talking 
about because we don’t have money’ (Male, 32 years 
old, rural area).
Knowledge and perception on malaria
A key issue was the level of knowledge of malaria, which 
influences preventive and treatment seeking behaviours. 
Some of the perceptions about cause of malaria dem-
onstrated by the participants (like the perception that 
consumption of fatty diets as well as spiritual attacks 
as a cause of malaria) were products of social construc-
tion from the different communities. All the participants 
identified the link between mosquitoes and malaria and 
they also were aware of some indirect causal factors, 
such as: dirty environment, living in dilapidated hous-
ing condition, stagnant waters around the house, among 
others. However, these indirect causal factors were 
perceived as direct causes of malaria by many of the 
participants.
‘What I know about malaria is that, some people 
say taking too much of oil -oil is one of the causes 
of malaria, palm oil. Another thing I know that 
causes it is like, for example, some people might be 
asked not to eat something like ‘egusi’, ‘egusi’ causes 
malaria too’ (Female, 49 years old, rural area).
As malaria is a common disease, which all the partici-
pants had experienced, knowledge of malaria symptoms 
was satisfactory among the participants. There were, 
however, some cultural and superstitious constructs and 
explanations for malaria infection; three participants 
said they believed some evil spiritual powers can cause 
malaria. This perception was reported in relation to 
the cause of malaria as well as the manifestation of the 
disease:
‘Some people say it’s a spiritual attack. You under-
stand. Because it was very mysterious -my mouth 
was very bitter but the symptoms were malaria 
symptoms. I don’t know if anything passed through 
the malaria’ (Female, 33 years old, urban area).
At one end of the continuum many of the participants 
saw malaria infection as life threatening; however, others 
saw it as a very common disease which is easy to treat 
hence not a life-threatening or serious infection.
‘Well, maybe because I am a Nigerian, I don’t see 
it as a life threatening disease. But I know that eh, 
when you travel abroad, they don’t want  to even 
hear that you have malaria. Malaria to us or to 
me personally, is like having headache. Am serious 
about that’ (Female, 40 years old, urban area).
Process
Malaria treatment‑seeking behaviours
When symptoms were experienced, socio-economic 
factors, like type of settlement, income level and type 
of job, tended to determine the treatment behaviours 
and, therefore, informed and determined the experience 
of the illness. This was in terms of first point of contact 
for treatment and choice of anti-malarial drugs; as these 
involved money, socioeconomic status was a deter-
minant. Conversely, other behaviours, like presump-
tive treatment, were reported across all socioeconomic 
groups in this study.
On experiencing malaria like symptoms, there are 
several facilities one can seek treatment in Nigeria: hos-
pitals/clinics, health centres, chemists/drug vendors, 
pharmacies and herbal healers. These facilities usually 
offer different treatment options ranging from a labo-
ratory diagnostic test prior, to presumptive treatment 
based on presenting symptoms. Those living in urban 
areas tended to use the pharmacy or hospital as the first 
point of contact whereas in the rural areas pharmacies 
and hospitals were less common as “chemists” were eas-
ier to access hence more used. With a large proportion 
(53%) of the Nigerian population living in rural areas, 
the chemists/drug vendors serves as the first point of 
contact for malaria treatment for many. The pharma-
cies provide professional and more expensive services 
whereas the drug vendors often lack the knowledge and 
skill which was reflected on both advice and cost of ser-
vices in these facilities. The chemist/drug vendor was 
the most reported first point of seeking malaria treat-
ment among participants whose monthly income was 
below the ₦18,000 (£63) minimum wage. Even when 
other sources were closely located, the chemists/drug 
vendors remained the most commonly used source for 
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malaria treatment by those of low socioeconomic sta-
tus. The seeming trust in the chemist/drug vendors by 
the rural dwellers was not based on their ability to offer 
more effective treatment than the hospitals, health centre 
or pharmacies. Rather, it was because, unlike the other 
sources, the chemist/drug vendors are more available and 
accessible through the provision of credit facility, cheaper 
alternatives, and convenient locations and out-of-hours 
services.
‘… hospital is not far from me, from where I leave… 
why I don’t go there is that those two chemists, they 
‘help’ me…. That’s why I go to theirs. So if I don’t have 
money they help me. If it’s the government hospital, 
everybody comes from different places to work. They 
will say pay us before we give you the drugs’ (Female, 
31 years old, rural area).
The participants were fully aware of the difference in 
standard between the pharmacies and the chemists, but 
both availability and low cost determined the use of the 
chemists.
‘The way we look at chemist in Nigeria is that chem-
ist is meant for, you know, people that are in the vil-
lages, you know that cannot afford (laughs) because 
in that chemist you see all sort of, manner of drugs… 
you see fake drugs there’ (Female, 44 years old, urban 
area).
Furthermore, when symptoms were severe or when 
seeking malaria treatment for children, most of the par-
ticipants would use hospital or pharmacies as the first 
point of treatment.
Presumptive diagnosis and treatment of malaria
Presumptive treatment of malaria, which involves treat-
ing suspected malaria cases based on presenting symp-
toms rather than a confirmatory diagnostic test [48], was 
the commonest approach and was found in all socioeco-
nomic groups. Those who mostly use the hospital for 
treatment, who were also the highest earners with the 
highest educational levels, reported the use of labora-
tory testing to confirm diagnosis more than those who 
use the chemist/drug vendors or pharmacies. The phar-
macies tended to implement treatment on the basis of 
presumptive diagnosis; and chemist/drug vendors almost 
entirely implemented treatment on the basis of presump-
tive diagnosis.
An example of this is with the three participants who 
reported they have never gone for a malaria diagnos-
tic test before (neither microscopy laboratory nor RDT) 
as they all used the chemist for most malaria treat-
ments. The most common reasons given by these par-
ticipants for this practice were their inability to afford the 
treatment cost, lack of access to hospitals and cultural 
factors. These three participants were rural dwellers and 
earned below the minimum wage of ₦18,000 (£63) per 
month.
‘…I don’t know whether some of the sicknesses I expe-
rience sometimes are malaria. I may –I might have 
had it, but I may not know it was malaria –I think I 
have told you that I have never gone for any malaria 
lab test to test me, to justify what is really my prob-
lem’ (Male, 32 years old, rural area).
Another reported behaviour with regards to presump-
tive treatment and the use of malaria diagnostic test prior 
to treatment was the practice of using previous results of 
malaria diagnostic test and the prescription received to 
treat subsequent episodes with similar symptoms. This 
was reported by two participants from the rural areas.
‘… sometimes, I go to the health centre. There was 
a time I went there and they ran a test and said its 
malaria and typhoid. They treated and gave me 
some drugs and also directed me to nearby phar-
macy to buy more drugs and add to the ones they 
gave me and take them all. After the treatment, 
when next I have malaria, I go to the pharmacy and 
buy the same drugs. Its not all the times that I have 
the money to run a test’ (Male, 55  years old, rural 
area).
In all, only one participant said she always used a diag-
nostic test to confirm she has malaria prior to her use 
of anti-malarial drugs. The other participants who also 
use laboratory diagnostic test prior to malaria treatment 
were not consistent as they also reported they practiced 
presumptive treatment. These were mostly participants 
who earned more than ₦100,000 per month. For the 
high-income earners in this study who practice presump-
tive treatment, affordability was not reported as a reason 
for this behaviour. The main reasons for this practice 
include: confident they can diagnose malaria and the per-
ception of presumptive treatment as time-saving route to 
malaria treatment.
Similarly, affordability was not always the key issue in 
decisions on the type of anti-malarial drug to get among 
different socioeconomic groups. The pharmacy attendant 
reported that most of the customers at the urban area are 
not really concerned about price but on the effectiveness 
of the drug, hence ACT was reported as the most sold 
class of anti-malarial drugs by the pharmacy attendant. 
This was however different in the rural areas and the low 
socio-economic groups; as would be expected, afford-
ability was an important issue for these groups. The cost 
of ACT was reported as out of reach by many rural and 
urban dwellers who earned below the national minimum 
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wage. As a result, monotherapies and non-ACT, like SP 
(which are cheaper and less effective in parasite clear-
ance), were reportedly the most used anti-malarial drugs 
by low-income earners and rural dwellers.
‘Like if severe, most of the people do not have enough 
money to treat themselves. They may tell you they 
need drugs of two hundred naira or one hundred 
and fifty naira. At times I have to use Laridox (sulf-
adoxine-pyrimethamine)’ (Male Drug Vendor, rural 
area).
Adherence to treatment guideline
As an important factor in the development of drug resist-
ance, adherence (in terms of completion of treatment 
course and administration of the proper dose at the cor-
rect time, in accordance with the WHO malaria treat-
ment guidelines [49] was considered in this study. Many 
participants reported non-adherence at least once in 
the last 6 months. Generally, reports of poor adherence 
were more common among participants of lower level 
of education and income level of below ₦50,000 (£177). 
However, some low-income participants, who reported 
a moderate level of adherence, saw anti-malarial drugs 
as expensive, so when they do buy them, they tend to 
complete the treatment as they do not want to waste 
their (expensive) treatment, and so wants value for their 
money.
‘There are times they will give me and I will take it 
and take it and take it, if the thing (malaria) clears, 
I will throw away the remaining. Even if its injec-
tion, I will not go to complete it. Because the thing 
(malaria) has cleared’ (Male, 55  years old, rural 
area).
‘Yes. If they give me drugs, I finish them. I don’t leave 
them because I used my money to buy them. Any 
drug they give me in the hospital I must take all of 
them. I don’t miss it. I don’t miss it as -are my not 
the one that will bear the pains? How can I miss 
it? If I don’t take it I will feel the sign in my body of 
course’ (Female, 35 years old, rural area).
While ideas of cost effectiveness encouraged adher-
ence in some low income earners, less commonly 
(mentioned only by two participants), it contributed to 
some non-adherence practices like stopping the treat-
ment to save the drug for future use. The practice of 
stopping to save drugs for future use was not common 
as most of the participants were wary of this practice 
as it was seen as risky and there was a fear of taking 
expired drugs.
‘When I buy and give him and he takes and gets bet-
ter and says he will not take anymore, I throw the 
rest away. Because when you keep it, do you know 
the day the sickness will come? By the time the 
sickness come, and u give it to him, it might bring 
another sickness for him because you don’t know if 
the drug has expired’ (Female, 31  years old, rural 
area).
Sharing of anti-malarial course among two or more 
people was also reported. One of the three participants 
who reported this behaviour was of high income (above 
₦300,000 (£1065) per month) and high educational 
level (postgraduate education). The difference between 
this participant’s behaviour and that of the other two (of 
income level below ₦18,000 (£63) and some primary 
school education) is that for the former, it was a one-off 
act because she could not buy a new course for a member 
of her household who got ill in the middle of the night; 
while for the later, it was reported as a recurrent behav-
iour. In most cases of sharing anti-malarial drugs with 
others, all parties involved end up not getting a complete 
treatment course.
Use of monotherapies
Generally, the knowledge of the names of anti-malarial 
drugs used was poor among the participants. Nevertheless, 
most of those who could identify the names of the anti-
malarial drugs they use reported artesunate as the most 
used anti-malarial drug, (five from the rural area reported 
using this drug compared to two from urban sites). Addi-
tionally, the drug vendor and pharmacy shop assistant that 
were interviewed also reported the sale of monotherapies 
(like artesunate) and non-artemisinin based combinations 
(like sulfadoxine-pyrimethamine (SP). The drug vendor in 
the rural area described a higher rate of monotherapy sale 
than the pharmacy attendant in the urban area. The major 
reason given for this by the drug vendor was the inability 
of the customers in the rural areas to afford the price for 
the artemisinin-based combination therapy, which is the 
first-line treatment for malaria in Nigeria.
Mixing
The concept and practice of ‘mixing’ was first mentioned 
in the initial interviews with participants from Zuba 
(rural area) in Abuja, and then subsequently in most of 
the interviews from other rural areas. To clearly under-
stand the practice of mixing and how it is done, a drug 
vendor from one of the communities in the rural areas 
and a pharmacy attendant from an urban area were 
interviewed. They described mixing as the practice of 
combining different drugs to treat malaria. It is done by 
including, for example, a dose from each of the included 
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drugs to form a mixed dose. There is no standard in 
terms of the number or types of drugs used in the mix-
ture for malaria treatment.
‘Almost all the people here normally mix drugs. They 
may come and say I need a malaria drug of fifty naira 
or hundred naira. … I don’t have much money to buy 
a complete one’ (Male Drug Vendor, from rural area).
Mixing was described as a very handy and flexible cop-
ing strategy by the low income earners. Also, all the par-
ticipants from the rural areas reported they mixed. The 
highest level of education attained by most of those who 
mixed was some primary education.
‘No I haven’t taken those packaged as complete 
course. The ones they mix, that’s the ones they buy 
for me. That’s the one our hand can get to. We only 
buy the ones we can afford’ (Female, age not known, 
rural area).
‘If you have up to five hundred naira or more, we can 
even mix Artesunate or Paracetamol or any analges-
tic, Panadol, Amoxil or Septrin’ (Male Drug Vendor, 
from rural area).
The anti-malarial drugs bought from the pharmacies 
were mostly sold as a complete course in their original 
packets. As the mixed drugs are sold in units of ‘one mixed 
dose’, a very important factor in determining how many 
doses of the mixture a customer gets is the amount they 
can afford. The customers can decide to buy a day’s dose or 
2 days’ dose and so on. While the complete course of anti-
malarial drugs like artemether-lumefantrine was reported 
to be about ₦800 (£2.84); ₦100 (£0.35 p) will get you a 
day dose of mixed anti-malarial drugs if you cannot afford 
₦800. Another important issue on the ‘mixing’ practice 
is that these drugs are not sold in their original packets as 
they are either cut up into bits or removed from the blister 
pack while being dispensed. Hence the customers/patients 
have little or no information about the individual drugs 
that constitute the mixture nor their expiry dates.
‘The last time I used anti-malarial drugs, I bought it 
from the chemist. They mixed the drugs for me. They 
mixed that of two days. … how they mix is, it depends 
on how many days’ dose you want them to mix for 
you’ (Male, 55 years old, rural area).
Outcome
As earlier stated there are four likely outcomes from the 
reported practices and behaviours indicated under the 
‘process’. These include recovery—which can be an indi-
cator of an effective malaria treatment; treatment fail-
ure—in the form of lack of response or worsening of the 
clinical manifestation of the infection after administering 
an anti-malarial course; resistance to anti-malarial drugs 
by the Plasmodium parasite; or death.
Some participants in this study discussed the outcomes 
of their malaria treatment experiences. Through the 
interview data, outcomes like death could not be explored 
since most participants were interviewed based on their 
own malaria treatment seeking behaviour. Although drug 
resistance was not directly measured/reported in this 
study, it is worth mentioning that malaria treatment fail-
ure can be an indicator of drug resistance [24].
Participants’ experiences of the outcomes were differ-
ent depending on reported practices and behaviours like 
the type of anti-malarial drug used, adherence to rec-
ommendation on how to administer the drugs, amongst 
others. On their last malaria treatment experience, treat-
ment failure was reported by three participants who used 
the mixed anti-malarial drugs. Only one of the partici-
pants who used a formal health facility during her last 
malaria episode reported treatment failure.
“… you just go to the chemist. Because the way I used 
to even treat my own, when it happens like that, 
there’s one chemist that is near our house, I will meet 
the woman and she will just mix drugs and give me. 
When she gives me I will just give them. They will 
take. Their body will be ok. When it is ok for like two 
days, before three days again, they will still com-
plain again. Before you know it, you carry they to 
the hospital” (Female, 31 years old, rural area).
“The difficulty I encounter sometimes is that there 
are sometimes that malaria will hold me down, and 
if I go and tell the chemists that malaria is disturb-
ing me, they will mix medicine for me and tell me 
how I will take them. Even after taking them, it will 
be like I didn’t take any medicine” (Male, 55  years 
old, rural area).
Nevertheless, on their last malaria episode, recovery 
or effective treatment was mostly reported in line with 
the practices of seeking treatment from a formal health 
facility and adhering to the recommended dose and com-
pleting the course. As the formal health facilities was 
reportedly used last time by mostly those from urban 
areas, many of those who reported effective treatment, 
without prior failure, were urban dwellers. However, one 
participant from rural area who used a hospital last time 
reported an outcome of effective treatment with no prior 
treatment failure.
“so I rushed to meet that doctor… he said its 
malaria. … he started giving me treatment. I didn’t 
even go to the farm for one week. I stayed home and 
took all the drugs when I took all the treatments I got 
myself ” (Female, 31 years old, rural area).
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As there are no detailed anti-malarial drug resist-
ance surveillance programmes in Nigeria, some of the 
reported cases of treatment failure, which can be drug 
resistance cases, go unreported and not recorded or fol-
lowed up. The lack of adequate care and surveillance 
for this potential cases of drug resistance can encourage 
further spread of resistant Plasmodium parasites in the 
population.
Discussion
The results of this study indicate that socioeconomic 
factors play important role in determining anti-malar-
ial drug use behaviours that promote drug resistance. 
To explicitly interpret the data on the malaria treat-
ment experiences and behaviours of the participants, 
and to create a holistic insight on how these contribute 
to anti-malarial drug resistance, the Donabedian model 
was adapted and used in this inquiry (see Fig.  2). The 
structure, mainly but not exclusively socioeconomic fac-
tors, determined the treatment seeking and drug use 
behaviours (process), which could in turn determine the 
outcome.
Evidently, social and economic contexts can influence 
behaviours as they contribute in shaping norms and in cre-
ating opportunities that promote certain behaviours [31]. 
Indeed, physical, social and economic environments can 
place constraints on an individual’s choices as well as that 
of a population. As shown in this study, income level and 
type of settlement, as structural factors, affect the decision 
on where to seek malaria treatment and whether or not a 
malaria diagnostic test will be used prior to treatment. In 
line with existing malaria studies in the Nigerian popula-
tion [8, 50, 51], the chemist/drug vendors and pharmacy 
were the major sources of malaria treatment. While some 
level of good practice and quality of care exists in the phar-
macies which are usually owned or managed by a trained 
pharmacist or health practitioner, the quality of care and 
practice in the chemists, which are owned and managed 
mostly by traders with little or no pharmaceutical train-
ing, remains a big public health concern in Nigeria. The 
chemists, which are the cheapest and most used source for 
malaria treatment in Nigeria are also the most likely place 
to get counterfeit anti-malarial drugs [52, 53].
Previous studies have shown that the cost of the origi-
nal drugs will influence the circulation of counterfeit 
anti-malarial drugs [54–56]. These counterfeit anti-
malarial drugs are usually sold cheaper than the origi-
nal ones; hence those in the low socioeconomic gradient 
constitute the target market for the counterfeiters. As 
long as ACT remains unaffordable to most Nigerians, 
the chemist will remain the main source of malaria treat-
ment, especially for the poor, and the circulation of fake 
anti-malarial drugs will flourish.
The study by Onwujekwe et  al. [53] on the quality 
of anti-malarial drugs provided by public and private 
healthcare providers in Southeast Nigeria found that 
37% of the anti-malarial drugs tested did not meet the 
United States Pharmacopoeia (USP) specifications for 
the amount of active ingredients as they either lacked 
the active drug ingredient or contained sub-therapeu-
tic quantities of it. Populations, like the Pailin province 
of Cambodia in SEA where artemisinin resistance have 
been confirmed have some similarity with the Nigerian 
population in terms of the existence of widely available 
cheap counterfeit anti-malarial drugs [57].
The public health danger of the sale of counterfeited 
drugs is that some of them contain inadequate quanti-
ties of the active ingredient which can encourage the 
development and spread of drug resistance by exposing 
the Plasmodium parasites to sub-therapeutic doses [58]. 
This creates a serious threat to vulnerable populations 
and jeopardises the progress and investments in malaria 
control [21]. Modelling analyses have also demonstrated 
that administration of under-dose of artemisinin plays 
an important part in the spread of artemisinin resistance 
[59].
In addition, the practice of mixing will have similar 
outcome in terms of encouraging the development and 
spread of anti-malarial drug resistance. With mixing, 
the patients can buy less or more number of doses than 
recommended. One of the dangers of using the mixed 
anti-malarial drugs is that it offers a safe route for the 
sale of expired and fake anti-malarial drugs as the mixed 
drugs are not sold or dispensed in their original packets. 
Another danger from this practice is the possibility that 
the interaction of the different drugs used in the mixture 
can alter the efficacy of these drugs when administered.
Furthermore, the low prevalence in this study, of some 
practices that are known to encourage the development 
of drug resistance, like sharing of malaria treatment 
course, stopping treatment to save drugs for future use, 
among others [60, 61], was not necessarily because of 
the main dangers associated with these practices. For 
instance, the practice of stopping treatment to save drugs 
was low among the participants because those more 
likely to do this (people of low socioeconomic status) 
used mostly mixed drugs for malaria treatment as they 
usually do not know the expiry date of the anti-malarial 
drugs. Hence, they expressed their fear that saving the 
drugs might mean taking expired anti-malarial drugs in 
the future. Also, it is possible that this practice of stop-
ping treatment to save drugs for future use, which pro-
motes the use of incomplete treatment course, could 
have been higher than reported if the participants had 
knowledge of the expiry dates of the anti-malarial drugs, 
especially those that use the mixed anti-malarial drugs.
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One of the behaviours that cut across different levels of 
socioeconomic measures in this study was presumptive 
treatment. Presumptive treatment has been identified as 
a major drive to drug over-use which promotes the devel-
opment and spread of resistance to anti-malarial drugs by 
the Plasmodium parasites [2]. Over-use of anti-malarial 
drug has been reported to increase the incident of altering 
within-host ecology of drug resistant parasites; and remov-
ing the drug-sensitive competitors has a significant impact 
on transmission potentials of drug resistant parasites [24].
Finally, the WHO recommended that the use of arte-
misinin monotherapies for treatment of uncomplicated 
malaria cases be banned as their use promotes the devel-
opment of resistance to artemisinin by the Plasmodium 
parasites. Nigeria was actually listed in the latest WHO 
malaria report [1] as one of the countries that have 
stopped the use of oral artemisinin monotherapies; how-
ever, these drugs (especially Artesunate) are still widely 
used and readily available in Nigeria and this threatens 
the efficacy of artemisinin both as monotherapies and 
in combination with other partner drugs. The wide use 
of monotherapies is another feature Nigeria shares with 
some of the countries in the Great Mekong region where 
artemisinin resistance has been confirmed.
Limitations of the study
One of the limitations of this study is that it did not 
further explore the role of socio-cultural factors in 
determining malaria treatment-seeking and drug use 
behaviours. Although some socio-cultural factors were 
identified in relation to malaria treatment, these were not 
further explored as the main focus of this study was on 
the contributory role of socioeconomic factors in deter-
mining treatment behaviours that promote anti-malarial 
drug resistance.
Also, this study is limited in terms of generalizability 
of the findings as it used a small sample and examined 
inhabitants of only two Nigerian areas. Nevertheless, 
the diversity of the participants, in terms of socio-demo-
graphic characteristics, ensures the transferability of the 
findings.
Conclusions and recommendations
Socioeconomic factors are major variables in determin-
ing behaviours and practices in malaria treatment. Most 
of the anti-malarial drug use behaviours that can pro-
mote resistance, which were reported in this study, were 
more among people of lower income level, low level 
of education, and of rural settlements. Behaviours and 
practices like mixing drugs for malaria treatment, use of 
monotherapies, saving anti-malarial drugs for future use, 
sharing of malaria drug/treatment course, among others 
are all coping strategies by the less well-off who cannot 
afford the recommended route to malaria treatment by 
the WHO.
To achieve a sustainable improvement in health, cam-
paigns should be targeted at social structures in the soci-
ety that produce diseases [31]. In malaria campaigns, 
there is need to broaden the scope of anti-malarial drug 
resistance control strategies to include strategies tar-
geted at improving the socioeconomic status of people in 
malaria endemic areas. Population-wide improvements 
in income, education, environmental and structural con-
ditions of rural dwellers in malaria endemic settings, like 
Nigeria, will encourage behavioural change on how anti-
malarial drugs are used.
Governments of malaria endemic countries should 
ensure existence and enforcement of policies and regu-
lations on anti-malarial drug distribution and dispens-
ing. However, this can only successfully reduce the rate 
of anti-malarial drug abuse if the existing underlying 
factors that promote these behaviours, like poverty, 
poor access to healthcare services, poor level of educa-
tion, social constructions, are first addressed. There is a 
need for the Nigerian government to review its policy 
on payment at the point of use for primary healthcare 
services as this constitutes a barrier to the use of for-
mal health facilities that provides better quality malaria 
treatment.
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